Condition: Vivax Malaria · Sponsor: Menzies School of Health Research
The goal of this clinical trial is to assess the efficacy and safety or a revised weight band tafenoquine dose in vivax malaria patients. The main question\[s\] it aims to answer are: * is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) non-inferior to high dose primaquine (7mg/kg over 7 days) * is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) superior to fixed dose tafenoquine (300mg) * is the tolerability and safety of TQRevised acceptable * is TQRevised acceptable and feasible Participants will receive a tafenoquine target dose 7.5mg/kg in weight bands. Researchers will compare this to patients receiving a fixed dose tafenoquine and high dose primaquine to see if safe and effective.
This description comes directly from the study's public registry record.
Hellen Mnjala · +610889468675 · hellen.mnjala@menzies.edu.au
kamala K Thriemer · +610889468644 · kamala.ley-thriemer@menzies.edu.au
Always discuss trial participation with your own doctor first.
| Dr Marcus Lacerda | Manaus, Brazil | Recruiting |
| Arba Minch General Hospital | Arba Minch, Ethiopia | Recruiting |
| Puskesmas Hanura | Hanura, Indonesia | Not Yet Recruiting |
| Dr Moses Laman and Dr Brioni Moore | Alexishafen, Papua New Guinea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06148792